Capricor Therapeutics CFO Sells Shares Amid Active Trading

Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, Inc. (NasdaqGS: CAPR), sold 24,100 shares of the company on June 25, 2026. The stock was trading at $26.44 on Tuesday. This insider transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Capricor Therapeutics, Inc.

On the same day, Bergmann also bought 24,100 shares at an average price of $3.18 before selling the same amount at $30.38. Similarly, Karen Krasney, Executive Vice President and General Counsel, mirrored these transactions, buying and selling 24,100 shares.

Other Institutional Activity in Capricor Therapeutics

Several institutional investors have been active in Capricor Therapeutics. Suvretta Capital Management, LLC increased its holdings by 2,032,990 shares, ending with 3,818,600 shares valued at approximately $116.1 million, marking a 113.9% increase. BlackRock, Inc. added 570,837 shares, bringing its total to 3,421,815 shares worth about $104 million, representing a 20% increase. Tang Capital Management LLC doubled its stake, adding 1,699,900 shares for a total of 3,399,900 shares valued at $103.4 million. State Street Corp boosted its position by 1,352,380 shares, now holding 2,181,901 shares valued at $66.3 million, a 163% increase. Vanguard Capital Management LLC opened a new position with 2,027,732 shares valued at $61.6 million.

Capricor Therapeutics, Inc. Stock Up 148.2%

Shares of Capricor Therapeutics traded near $26.44 on Tuesday. The company has a market cap of about $1.53 billion and is not currently profitable, with a forward P/E ratio of -41.17. The stock has a 52-week low of $4.30 and a high of $40.37. Its 50-day moving average is $30.15, while the 200-day moving average stands at $21.95. The company maintains a strong liquidity position with a current ratio of 8.42 and a quick ratio of 8.28.

Analysts Set New Price Targets

Analysts have maintained a bullish outlook on Capricor Therapeutics. On March 13, 2026, B. Riley Securities maintained a 'buy' rating with a $63.00 price target. Piper Sandler reiterated a 'buy' rating with a $58.00 target on the same day. HC Wainwright & Co. reiterated their 'buy' rating with a $60.00 target on March 10, 2026. The consensus among analysts remains a strong buy, with an average target price of $53.60 based on 10 analyst opinions.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a biotechnology company based in San Diego, California. It focuses on developing cell and exosome-based therapies for diseases with unmet needs, such as Duchenne muscular dystrophy (DMD). The company’s lead product, Deramiocel, is in phase 3 clinical trials for DMD. Capricor also develops vaccines and therapeutic platforms, including an exosome-based vaccine candidate in phase 1 clinical studies.

Bottom Line

Capricor Therapeutics remains a company of interest due to its innovative approach to treating serious diseases. The recent insider transactions and institutional activities highlight active interest in the company's stock. Despite the backward-looking nature of these reports, investors closely watch these developments for insights into potential future performance.